Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents

American Journal of Pathology

Volumn 168, Issue 4, 2006, Pages 1107-1118

  Li, Ying Chun ^a,b   Park, Mi Jung ^a,b   Ye, Sang Kyu ^b   Kim, Chul Woo ^b   Kim, Yong Nyun ^a,b  

^a National Cancer Center   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOCHOLESTEROLEMIC AGENT; METHYL BETA CYCLODEXTRIN; PROTEIN BCL XL; PROTEIN KINASE B;

ANOIKIS; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CAVEOLA; CELL FUNCTION; CELL SURFACE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 33645457007     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050959     Document Type: Article

References (62)

1. Galbiati F, Razani B, Lisanti MP: Emerging themes in lipid rafts and caveolae. Cell 2001, 106:403-411
2. Waugh MG, Minogue S, Anderson JS, dos Santos M, Hsuan JJ: Signalling and non-caveolar rafts. Biochem Soc Trans 2001, 29:509-511
3. Harder T: Lipid raft domains and protein networks in T-cell receptor signal transduction. Curr Opin Immunol 2004, 16:353-359
4. Muppidi JR, Siegel RM: Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol 2004, 5:182-189
5. Gniadecki R: Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 2004, 320:165-169
6. Carpenter G: The EGF receptor: a nexus for trafficking and signaling. Bioessays 2000, 22:697-707
7. Zajchowski LD, Robbins SM: Lipid rafts and little caves: compartmentalized signalling in membrane microdomains. Eur J Biochem 2002, 269:737-752
8. Silvius JR: Role of cholesterol in lipid raft formation: lessons from lipid model systems. Biochim Biophys Acta 2003, 1610:174-183
9. London E, Brown DA: Insolubility of lipids in Triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 2000, 1508:182-195
10. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000, 1:31-39
11. Scheel-Toellner D, Wang K, Singh R, Majeed S, Raza K, Curnow SJ, Salmon M, Lord JM: The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun 2002, 297:876-879
12. Freeman MR, Solomon KR: Cholesterol and prostate cancer. J Cell Biochem 2004, 91:54-69
13. Kolanjiappan K, Ramachandran CR, Manoharan S: Biochemical changes in tumor tissues of oral cancer patients. Clin Biochem 2003, 36:61-65
14. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE: Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003, 101:3628-3634
15. Duncan RE, El-Sohemy A, Archer MC: Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem 2004, 279:33079-33084
16. El-Sohemy A, Archer MC: Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations. Carcinogenesis 2000, 21:827-831
17. Bennis F, Favre G, Le Gaillard F, Soula G: Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549. Int J Cancer 1993, 55:640-645
18. Shimamura H, Terada Y, Okado T, Tanaka H, Inoshita S, Sasaki S: The PI3-kinase-Akt pathway promotes mesangial cell survival and inhibits apoptosis in vitro via NF-kappa B and Bad. J Am Soc Nephrol 2003, 14:1427-1434
19. Romashkova JA, Makarov SS: NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999, 401:86-90
20. Panka DJ, Mano T, Suhara T, Walsh K, Mier JW: Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem 2001, 276:6893-6896
21. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241
22. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1321
23. Kane LP, Shapiro VS, Stokoe D, Weiss A: Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999, 9:601-604
24. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J: NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001, 21:5299-5305
25. Chen C, Edelstein LC, Gelinas C: The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000, 20:2687-2695
26. Partovian C, Simons M: Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal 2004, 16:951-957
27. Elhyany S, Assa-Kunik E, Tsory S, Muller T, Fedida S, Segal S, Fishman D: The integrity of cholesterol-enriched microdomains is essential for the constitutive high activity of protein kinase B in tumour cells. Biochem Soc Trans 2004, 32:837-839
28. Hill MM, Feng J, Hemmings BA: Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 2002, 12:1251-1255
29. Kim YN, Wiepz GJ, Guadarrama AG, Bertics PJ: Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1: enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status. J Biol Chem 2000, 275:7481-7491
30. Chen X, Resh MD: Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor. J Biol Chem 2002, 277:49631-49637
31. Westover EJ, Covey DF, Brockman HL, Brown RE, Pike LJ: Cholesterol depletion results in site-specific increases in epidermal growth factor receptor phosphorylation due to membrane level effects: studies with cholesterol enantiomers. J Biol Chem 2003, 278:51125-51133
32. Kim YN, Bertics PJ: The endocytosis-linked protein dynamin associates with caveolin-1 and is tyrosine phosphorylated in response to the activation of a noninternalizing epidermal growth factor receptor mutant. Endocrinology 2002, 143:1726-1731
33. Downward J: PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004, 15:177-182
34. Gopalakrishna P, Rangaraj N, Pande G: Cholesterol alters the interaction of glycosphingolipid GM3 with alpha5beta1 integrin and increases integrin-mediated cell adhesion to fibronectin. Exp Cell Res 2004, 300:43-53
35. Gopalakrishna P, Chaubey SK, Manogaran PS, Pande G: Modulation of alpha5beta1 integrin functions by the phospholipid and cholesterol contents of cell membranes. J Cell Biochem 2000, 77:517-528
36. Ravid D, Maor S, Werner H, Liscovitch M: Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 2005, 24:1338-1347
37. Hino M, Doihara H, Kobayashi K, Aoe M, Shimizu N: Caveolin-1 as tumor suppressor gene in breast cancer. Surg Today 2003, 33:486-490
38. Li L, Ren CH, Tahir SA, Ren C, Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 2003, 23:9389-9404
39. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991, 139:271-279
40. Denoyelle C, Albanese P, Uzan G, Hong L, Vannier JP, Soria J, Soria C: Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 2003, 15:327-338
41. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G: The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004, 104:1825-1832
42. Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19
43. Seeger H, Wallwiener D, Mueck AO: Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 2003, 111:47-48
44. Brazil DP, Park J, Hemmings BA: PKB binding proteins: getting in on the Akt. Cell 2002, 111:293-303
45. Oxhorn BC, Buxton IL: Caveolar compartmentation of caspase-3 in cardiac endothelial cells. Cell Signal 2003, 15:489-496
46. Mineo C, Gill GN, Anderson RG: Regulated migration of epidermal growth factor receptor from caveolae. J Biol Chem 1999, 274:30636-30643
47. Grossmann J: Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 2002, 7:247-260
48. Frisch SM, Ruoslahti E: Integrins and anoikis. Curr Opin Cell Biol 1997, 9:701-706
49. Xia H, Nho RS, Kahm J, Kleidon J, Henke CA: Focal adhesion kinase is upstream of phosphatidylinositol 3-kinase/Akt in regulating fibroblast survival in response to contraction of type I collagen matrices via a beta 1 integrin viability signaling pathway. J Biol Chem 2004, 279:33024-33034
50. Walden PD, Globina Y, Nieder A: Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase. Urol Res 2004, 32:261-265
51. Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD: Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem 1997, 272:26056-26061
52. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR: Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002, 62:2227-2231
53. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR: Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005, 115:959-968
54. Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A, Ohno R: Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 2000, 14:1444-1450
55. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H: Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 1994, 84:2689-2698
56. Mo H, Elson CE: Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004, 229:567-585
57. Wong WW, Dimitroulakos J, Minden MD, Penn LZ: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16:508-519
58. Splichal JE, Stamm JA, Ornstein DL: The statins: multifunctional antithrombotic and antineoplastic drugs. Semin Thromb Hemost 2003, 29:259-274
59. Thompson TC, Timme TL, Li L, Goltsov A: Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 1999, 4:233-237
60. Devarajan E, Sahin AA, Chen JS, Krishnamurthy RR, Aggarwal N, Brun AM, Sapino A, Zhang F, Sharma D, Yang XH, Tora AD, Mehta K: Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002, 21:8843-8851
61. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M, Lisanti MP: Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in TRAMP mice. J Biol Chem 2005, 280:25134-25145
62. Williams TM, Lisanti MP: Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005, 288:C494-C506